Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15523068 | 0.79 | LMNA (0.42) | MAPTMEN1ALOX15TSHRKMT2A | |
| SCHEMBL15523444 | 0.78 | PRMT3 (0.38) | GPBAR1ALDH1A1MEN1ALOX15KMT2A | |
| SCHEMBL15522834 | 0.75 | BRD4 (0.61) | ALDH1A1HPGDKMT2A | |
| SCHEMBL27988819 | 0.72 | GPBAR1 (0.54) | GPBAR1 | |
| SCHEMBL6025353 | 0.71 | ALDH1A1 (0.62) | ALDH1A1MAPTKDM4EMEN1HPGD | |
| Hydrochloric Acid SCHEMBL27988803 | 0.71 | GPBAR1 (0.53) | GPBAR1 | |
| SCHEMBL15523890 | 0.71 | GPBAR1 (0.43) | GPBAR1OPRM1OPRL1 | |
| SCHEMBL17075119 | 0.71 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EMEN1HPGD | |
| SCHEMBL15933941 | 0.70 | GPBAR1 (0.59) | GPBAR1 | |
| SCHEMBL17075184 | 0.70 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | disclosed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | disclosed |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | GPBAR1 201/4885ALDH1A1 3553/4885MAPT 3416/4885 |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | GPBAR1 201/4885ALDH1A1 3553/4885MAPT 3416/4885 |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | HTR2C, HTR2A, HTR5A | GPBAR1 201/4885ALDH1A1 3553/4885MAPT 3416/4885 |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | GPBAR1 201/4885ALDH1A1 3553/4885MAPT 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.